服用绥美凯伤肝肾吗

Suimeike (dolute abalamide tablets) is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir. Today we will take a closer look at whether taking Suimeikai (Doteta Abalami Tablets) will harm the liver and kidneys?

Taking Suimeikai (Dotiabalamid Tablets) has a certain impact on liver and kidney function. This requires active liver-protecting treatment and kidney-protecting treatment, and the treatment plan can be changed if necessary.

Geriatric Patients There are limited data on the use of dolutegravir, abacavir, and lamivudine in patients aged ≥65 years, and there is no evidence that older patients require different doses than younger adult patients. Taking into account age-related changes, such as decreased renal function and changes in hematological parameters, special caution is recommended when using Trimax in this age group.

Patients with renal impairment whose creatinine clearance is less than 50 mL/min are not recommended to take Suimeikai (Doteta abalamide tablets).

Hepatic Impairment Abacavir is primarily metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment; therefore, the use of Trimax (doluteabalamide) is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels if feasible.

Pediatric Population The safety and effectiveness of Suimeike (dolute abalamib tablets) in children under 12 years of age has not been established. No data yet. Method of Administration: This product can be taken orally with or without food.

Suimeike (dolutegravir tablets) is the only three-in-one compound drug containing dolutegravir (DTG), which integrates treatment drugs for different stages of viral infection in the same tablet. Patients only need to take one drug to achieve the effect of combined medication. Suimeike (dolute abalamib tablets) has been approved for marketing in 50 countries and regions, and has been recommended by many authoritative academic institutions and authoritative guidelines in Europe and the United States as the first-line treatment of choice for patients with newly diagnosed HIV infection.

The above is what you should pay attention to when taking Suimeikai (Doteta Abalami Tablets). I hope it can help you!